Fred Doloresco
University at Buffalo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Fred Doloresco.
Pharmacotherapy | 2009
Daniel R. Touchette; Fred Doloresco; Katie J. Suda; Alexandra Perez; S.J. Turner; Yash J. Jalundhwala; Maria C. Tangonan; James M. Hoffman
Studies have consistently evidenced the positive clinical, economic, and humanistic benefits of pharmacist‐directed patient care in a variety of settings. Given the vast differences in clinical outcomes associated with evaluated clinical pharmacy services (CPS), more detail as to the nature of the CPS is needed to better understand observed differences in economic outcomes. With the growing trend of outpatient pharmacy services, these economic evaluations serve as viable decision‐making tools in choosing the most effective and cost‐effective pharmacy programs. We previously conducted three systematic reviews to evaluate the economic impact of CPS from 1988 to 2005. In this systematic review, our objectives were to describe and evaluate the quality of economic evaluations of CPS published between 2006 and 2010, with the goal of informing administrators and practitioners as to their cost‐effectiveness. We searched the scientific literature by using the Medline, International Pharmaceutical Abstracts, Embase, and Cumulative Index to Nursing and Allied Health Literature databases to identify studies describing CPS published from 2006 to 2010. Studies meeting our inclusion criteria (original research articles that evaluated CPS and described economic and clinical outcomes) were reviewed by two investigators. Methodology used, economic evaluation type, CPS setting and type, and clinical and economic outcome results were extracted. Results were informally compared with previous systematic reviews. Of 3587 potential studies identified, 25 met inclusion criteria. Common CPS settings were hospital (36%), community (32%), and clinic or hospital‐based ambulatory practices (28%). CPS types were disease state management (48%), general pharmacotherapeutic monitoring (24%), target drug programs (8%), and patient education (4%). Two studies (8%) listed CPS as medication therapy management. Costs were evaluated in 24 studies (96%) and sufficiently described in 13 (52%). Clinical or humanistic outcomes were evaluated in 20 studies (80%) and were sufficiently described in 18 (72%). Control groups were included in 16 (70%) of 23 studies not involving modeling. Study assumptions and limitations were stated and justified in eight studies (32%). Conclusions and recommendations were considered justified and based on results in 24 studies (96%). Eighteen studies (72%) involved full economic evaluation. The mean ± SD study quality score for full economic evaluations (18 studies) was 60.4 ± 22.3 of a possible 100 points. Benefit‐cost ratios from three studies ranged from 1.05:1 to 25.95:1, and incremental cost‐effectiveness ratios of five studies were calculated and reported. Fewer studies documented the economic impact of CPS from 2006–2010 than from 2001–2005, although a higher proportion involved controlled designs and were full economic evaluations. Evaluations of ambulatory practices were increasingly common. CPS were generally considered cost‐effective or provided a good benefit‐cost ratio.
American Journal of Health-system Pharmacy | 2012
James M. Hoffman; Edward C. Li; Fred Doloresco; Linda Matusiak; Robert J. Hunkler; Nilay D. Shah; Lee C. Vermeulen; Glen T. Schumock
PURPOSE Factors likely to influence drug expenditures, drug expenditure trends in 2010 and 2011, and projected drug expenditures for 2012 are discussed. SUMMARY Data were analyzed to provide drug expenditure trends for total drug expenditures and the hospital and clinic sectors. Data were obtained from the IMS Health National Sales Perspectives database. From 2009 to 2010, total U.S. drug expenditures increased by 2.7%, with total spending rising from
American Journal of Health-system Pharmacy | 2009
Fred Doloresco; Lee C. Vermeulen
299.2 billion to
American Journal of Health-system Pharmacy | 2009
James M. Hoffman; Nilay D. Shah; Lee C. Vermeulen; Fred Doloresco; Patrick Martin; Sharon Blake; Linda Matusiak; Robert J. Hunkler; Glen T. Schumock
307.5 billion. Drug expenditures in clinics grew by 6.0% from 2009 to 2010. Hospital drug expenditures increased at the moderate rate of 1.5% from 2009 to 2010; through the first nine months of 2011, hospital drug expenditures increased by only 0.3% compared with the same period in 2010. The dominant trend over the past several years is substantial moderation in expenditure growth for widely used drugs, primarily due to the ongoing introduction and wide use of generic versions of high-cost, frequently used medications. At the end of 2010, generic drugs accounted for 78% of all retail prescriptions dispensed. Another pattern is substantial increases in expenditures for specialized medications, particularly in the outpatient setting as growth in prescription drug expenditures for clinic-administered drugs consistently outpaces growth in total expenditures. Various factors are likely to influence drug expenditures in 2012, including drugs in development, the diffusion of new drugs, generic drugs, drug shortages, and biosimilars. CONCLUSION For 2012, we project a 3-5% increase in total drug expenditures across all settings, a 5-7% increase in expenditures for clinic-administered drugs, and a 0-2% increase in hospital drug expenditures.
American Journal of Health-system Pharmacy | 2011
Fred Doloresco; Cory E. Fominaya; Glen T. Schumock; Lee C. Vermeulen; Linda Matusiak; Robert J. Hunkler; Nilay D. Shah; James M. Hoffman
PURPOSE The current state of hospital pharmacy practice around the globe and key issues facing international hospital pharmacy practice were studied. METHODS This survey assessed multiple aspects of hospital pharmacy practice within each of the Member States recognized by the United Nations. An official respondent from each nation was identified by a structured nomination process. The survey instrument was developed; pilot tested; translated into English, French, and Spanish; and distributed in July 2007. The nature, scope, and breadth of hospital pharmacy practices in medication procurement, prescribing, preparation and distribution, administration, outcomes monitoring, and human resources and training were evaluated. Descriptive statistics were used to characterize the responses. RESULTS Eighty-five countries (44% of the 192 Member States) responded to the survey. The respondent sample of countries was representative of all nations in terms of population, geographic region, World Health Organization region, and level of economic development. In addition to qualifying the nature of hospital pharmacy practice, the survey highlighted numerous challenges facing the profession of pharmacy in the hospital setting around the globe, including access to medicines and adequately trained pharmacists. CONCLUSION While the practice of hospital pharmacy differs from country to country, many nations face similar challenges, regardless of their population, location, or wealth. These survey results provide a basis for identifying opportunities for growth and development, as well as for international collaboration, to advance the profession of pharmacy and ensure that patients worldwide receive the care that they deserve.
American Journal of Health-system Pharmacy | 2008
James M. Hoffman; Nilay D. Shah; Lee C. Vermeulen; Fred Doloresco; Penny Grim; Robert J. Hunkler; Karrie M. Hontz; Glen T. Schumock
PURPOSE Drug expenditure trends in 2007 and 2008, projected drug expenditures for 2009, and factors likely to influence drug expenditures are discussed. SUMMARY Various factors are likely to influence drug expenditures in 2009, including drugs in development, the diffusion of new drugs, drug safety concerns, generic drugs, Medicare Part D, and changes in the drug supply chain. The increasing availability of important generic drugs and drug safety concerns continue to moderate growth in drug expenditures. The drug supply chain remains dynamic and may influence drug expenditures, particularly in specialized therapeutic areas. Initial data suggest that the Medicare Part D benefit has influenced drug expenditures, but the ultimate impact of the benefit on drug expenditures remains unclear. From 2006 to 2007, total U.S. drug expenditures increased by 4.0%, with total spending rising from
PharmacoEconomics | 2010
William A. Prescott; Fred Doloresco; Jack Brown; Joseph A. Paladino
276 billion to
American Journal of Health-system Pharmacy | 2010
James M. Hoffman; Fred Doloresco; Lee C. Vermeulen; Nilay D. Shah; Linda Matusiak; Robert J. Hunkler; Glen T. Schumock
287 billion. Drug expenditures in clinics continue to grow more rapidly than in other settings, with a 9.9% increase from 2006 to 2007. Hospital drug expenditures increased at a moderate rate of only 1.6% from 2006 to 2007; through the first nine months of 2008, hospital drug expenditures increased by only 2.8% compared with the same period in 2007. CONCLUSION In 2009, we project a 0-2% increase in drug expenditures in outpatient settings, a 1-3% increase in expenditures for clinic-administered drugs, and a 1-3% increase in hospital drug expenditures.
American Journal of Hospice and Palliative Medicine | 2011
Shelley Wilson; Robert Wahler; Jack Brown; Fred Doloresco; Scott V. Monte
PURPOSE. Drug expenditure trends in 2009 and 2010, projected drug expenditures for 2011, and factors likely to influence drug expenditures are discussed. SUMMARY. Various factors are likely to influence drug expenditures in 2011, including drugs in development, the diffusion of new drugs, generic drugs, health care reform, and biosimilars. Two distinct patterns of drug expenditures continue to exist. The dominant trend over the past several years is substantial moderation in expenditure growth for widely used drugs, primarily due to the ongoing introduction of generic medications for high-cost, frequently used medications and the influence of the economic downturn. The second pattern is substantial increases in expenditures for specialized medications, particularly in the outpatient setting. The influence of health care reform, the economy, and the emergence of biosimilars will be important trends to follow over the next several years, but they are unlikely to have substantial impact on drug expenditures in 2011. From 2008 to 2009, total U.S. drug expenditures increased by 5.2%, with total spending rising from
American Journal of Health-system Pharmacy | 2013
James M. Hoffman; Edward C. Li; Fred Doloresco; Linda Matusiak; Robert J. Hunkler; Nilay D. Shah; Lee C. Vermeulen; Glen T. Schumock
284.8 billion to